Motofen

Crying, Lazy Eye, Slow Heart Rate + 31 more

Treatment

3 FDA approvals

20 Active Studies for Motofen

What is Motofen

Atropine

The Generic name of this drug

Treatment Summary

Atropine is an alkaloid, which is a type of organic compound, originally derived from the Atropa belladonna plant but also found in other plants, primarily in the family Solanaceae.

Lomotil

is the brand name

image of different drug pills on a surface

Motofen Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Lomotil

Atropine

1960

151

Approved as Treatment by the FDA

Atropine, otherwise known as Lomotil, is approved by the FDA for 3 uses which include Sinus Bradycardia and Carbamates .

Sinus Bradycardia

Carbamates

Used to treat Toxic effect of organophosphate and carbamate in combination with Pralidoxime

muscarinic side effects

Helps manage muscarinic side effects

Effectiveness

How Motofen Affects Patients

Atropine is a medicine that blocks the effects of the chemical acetylcholine. It can be used to slow down heart rate, increase respiration rate, and dilate the pupils. Its effects can last longer than those of scopolamine. Atropine can be used to treat abnormal heart rhythms caused by nerve signals, and can prevent low blood pressure caused by other drugs. It is also used in eye treatments. In some cases, atropine can cause problems like acute glaucoma, complete blockage of the stomach, urinary retention, thickening of respiratory secretions, and lung disease.

How Motofen works in the body

Atropine blocks the effects of acetylcholine, a chemical that's important for nerve and muscle functions. It works by competing with acetylcholine for receptors in the body, so it can't activate them. This blocks the effects of acetylcholine on tissues such as muscles, the nervous system, and glands. It also affects smooth muscles that naturally respond to acetylcholine. The effects of atropine can be reversed by increasing the amount of acetylcholine present.

When to interrupt dosage

The dosage of Motofen is contingent upon the distinguished illness, including Bronchospasm, Bile fluid and Muscle Hypertonia. The measure of dosage may differ, in line with the technique of conveyance (e.g. Oral or Injection - Intramuscular) specified in the table hereunder.

Condition

Dosage

Administration

Crying

0.025 mg, , 0.0194 mg/mL, 0.1 mg/mL, 0.0194 mg, 1.0 mg/mL, 4.0 mg/mL, 0.4 mg/mL, 10.0 mg/mL, 0.05 mg/mL, 0.14 mg/mL, 0.0582 mg, 0.4 mg, 0.6 mg, 1.0 %, 0.1 mg, 10.0 mg, 0.8 mg, 0.3 mg, 1.0 mg, 3.0 mg, 0.0097 mg, 0.025 mg/mL, 5.0 mg/mL, 20.0 mg/mL, 2.5 mg/mL, 0.5 mg, 0.01 mg/mg, 0.019 mg/mL, 21.0 mg/mL, 0.03 mg, 0.6 mg/mL, 0.00194 mg/mL, 0.8 mg/mL, 0.3 mg/mL, 0.5 mg/mL

, Tablet, Elixir, Elixir - Oral, Oral, Tablet - Oral, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Injection, solution - Endotracheal; Intramuscular; Intravenous; Subcutaneous, Endotracheal; Intramuscular; Intravenous; Subcutaneous, Parenteral, Injection, Injection - Parenteral, Injection - Intramuscular; Intravenous; Subcutaneous, Solution - Ophthalmic, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Solution, Intramuscular, Injection, solution - Intramuscular, Intravenous, Injection, solution - Intravenous, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Solution - Intramuscular; Intravenous; Subcutaneous, Tablet, extended release, Tablet, extended release - Oral, Liquid - Ophthalmic, Liquid, Liquid - Intravenous, Ointment, Ointment - Ophthalmic, Capsule, Capsule - Oral, Liquid - Oral, Solution - Oral, Injection - Intramuscular, Kit, Kit - Intramuscular, Respiratory (inhalation), Endotracheal; Intramedullary; Intramuscular; Intravenous; Subcutaneous, Injection, solution - Endotracheal; Intramedullary; Intramuscular; Intravenous; Subcutaneous, Intravenous; Parenteral, Injection - Intravenous; Parenteral, Injection - Intravenous, Injection - Endotracheal; Intramedullary; Intramuscular; Intravenous; Subcutaneous

Lazy Eye

0.025 mg, , 0.0194 mg/mL, 0.1 mg/mL, 0.0194 mg, 1.0 mg/mL, 4.0 mg/mL, 0.4 mg/mL, 10.0 mg/mL, 0.05 mg/mL, 0.14 mg/mL, 0.0582 mg, 0.4 mg, 0.6 mg, 1.0 %, 0.1 mg, 10.0 mg, 0.8 mg, 0.3 mg, 1.0 mg, 3.0 mg, 0.0097 mg, 0.025 mg/mL, 5.0 mg/mL, 20.0 mg/mL, 2.5 mg/mL, 0.5 mg, 0.01 mg/mg, 0.019 mg/mL, 21.0 mg/mL, 0.03 mg, 0.6 mg/mL, 0.00194 mg/mL, 0.8 mg/mL, 0.3 mg/mL, 0.5 mg/mL

, Tablet, Elixir, Elixir - Oral, Oral, Tablet - Oral, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Injection, solution - Endotracheal; Intramuscular; Intravenous; Subcutaneous, Endotracheal; Intramuscular; Intravenous; Subcutaneous, Parenteral, Injection, Injection - Parenteral, Injection - Intramuscular; Intravenous; Subcutaneous, Solution - Ophthalmic, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Solution, Intramuscular, Injection, solution - Intramuscular, Intravenous, Injection, solution - Intravenous, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Solution - Intramuscular; Intravenous; Subcutaneous, Tablet, extended release, Tablet, extended release - Oral, Liquid - Ophthalmic, Liquid, Liquid - Intravenous, Ointment, Ointment - Ophthalmic, Capsule, Capsule - Oral, Liquid - Oral, Solution - Oral, Injection - Intramuscular, Kit, Kit - Intramuscular, Respiratory (inhalation), Endotracheal; Intramedullary; Intramuscular; Intravenous; Subcutaneous, Injection, solution - Endotracheal; Intramedullary; Intramuscular; Intravenous; Subcutaneous, Intravenous; Parenteral, Injection - Intravenous; Parenteral, Injection - Intravenous, Injection - Endotracheal; Intramedullary; Intramuscular; Intravenous; Subcutaneous

Slow Heart Rate

0.025 mg, , 0.0194 mg/mL, 0.1 mg/mL, 0.0194 mg, 1.0 mg/mL, 4.0 mg/mL, 0.4 mg/mL, 10.0 mg/mL, 0.05 mg/mL, 0.14 mg/mL, 0.0582 mg, 0.4 mg, 0.6 mg, 1.0 %, 0.1 mg, 10.0 mg, 0.8 mg, 0.3 mg, 1.0 mg, 3.0 mg, 0.0097 mg, 0.025 mg/mL, 5.0 mg/mL, 20.0 mg/mL, 2.5 mg/mL, 0.5 mg, 0.01 mg/mg, 0.019 mg/mL, 21.0 mg/mL, 0.03 mg, 0.6 mg/mL, 0.00194 mg/mL, 0.8 mg/mL, 0.3 mg/mL, 0.5 mg/mL

, Tablet, Elixir, Elixir - Oral, Oral, Tablet - Oral, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Injection, solution - Endotracheal; Intramuscular; Intravenous; Subcutaneous, Endotracheal; Intramuscular; Intravenous; Subcutaneous, Parenteral, Injection, Injection - Parenteral, Injection - Intramuscular; Intravenous; Subcutaneous, Solution - Ophthalmic, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Solution, Intramuscular, Injection, solution - Intramuscular, Intravenous, Injection, solution - Intravenous, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Solution - Intramuscular; Intravenous; Subcutaneous, Tablet, extended release, Tablet, extended release - Oral, Liquid - Ophthalmic, Liquid, Liquid - Intravenous, Ointment, Ointment - Ophthalmic, Capsule, Capsule - Oral, Liquid - Oral, Solution - Oral, Injection - Intramuscular, Kit, Kit - Intramuscular, Respiratory (inhalation), Endotracheal; Intramedullary; Intramuscular; Intravenous; Subcutaneous, Injection, solution - Endotracheal; Intramedullary; Intramuscular; Intravenous; Subcutaneous, Intravenous; Parenteral, Injection - Intravenous; Parenteral, Injection - Intravenous, Injection - Endotracheal; Intramedullary; Intramuscular; Intravenous; Subcutaneous

Cholinesterase Inhibitors

0.025 mg, , 0.0194 mg/mL, 0.1 mg/mL, 0.0194 mg, 1.0 mg/mL, 4.0 mg/mL, 0.4 mg/mL, 10.0 mg/mL, 0.05 mg/mL, 0.14 mg/mL, 0.0582 mg, 0.4 mg, 0.6 mg, 1.0 %, 0.1 mg, 10.0 mg, 0.8 mg, 0.3 mg, 1.0 mg, 3.0 mg, 0.0097 mg, 0.025 mg/mL, 5.0 mg/mL, 20.0 mg/mL, 2.5 mg/mL, 0.5 mg, 0.01 mg/mg, 0.019 mg/mL, 21.0 mg/mL, 0.03 mg, 0.6 mg/mL, 0.00194 mg/mL, 0.8 mg/mL, 0.3 mg/mL, 0.5 mg/mL

, Tablet, Elixir, Elixir - Oral, Oral, Tablet - Oral, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Injection, solution - Endotracheal; Intramuscular; Intravenous; Subcutaneous, Endotracheal; Intramuscular; Intravenous; Subcutaneous, Parenteral, Injection, Injection - Parenteral, Injection - Intramuscular; Intravenous; Subcutaneous, Solution - Ophthalmic, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Solution, Intramuscular, Injection, solution - Intramuscular, Intravenous, Injection, solution - Intravenous, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Solution - Intramuscular; Intravenous; Subcutaneous, Tablet, extended release, Tablet, extended release - Oral, Liquid - Ophthalmic, Liquid, Liquid - Intravenous, Ointment, Ointment - Ophthalmic, Capsule, Capsule - Oral, Liquid - Oral, Solution - Oral, Injection - Intramuscular, Kit, Kit - Intramuscular, Respiratory (inhalation), Endotracheal; Intramedullary; Intramuscular; Intravenous; Subcutaneous, Injection, solution - Endotracheal; Intramedullary; Intramuscular; Intravenous; Subcutaneous, Intravenous; Parenteral, Injection - Intravenous; Parenteral, Injection - Intravenous, Injection - Endotracheal; Intramedullary; Intramuscular; Intravenous; Subcutaneous

Kidney Calculi

0.025 mg, , 0.0194 mg/mL, 0.1 mg/mL, 0.0194 mg, 1.0 mg/mL, 4.0 mg/mL, 0.4 mg/mL, 10.0 mg/mL, 0.05 mg/mL, 0.14 mg/mL, 0.0582 mg, 0.4 mg, 0.6 mg, 1.0 %, 0.1 mg, 10.0 mg, 0.8 mg, 0.3 mg, 1.0 mg, 3.0 mg, 0.0097 mg, 0.025 mg/mL, 5.0 mg/mL, 20.0 mg/mL, 2.5 mg/mL, 0.5 mg, 0.01 mg/mg, 0.019 mg/mL, 21.0 mg/mL, 0.03 mg, 0.6 mg/mL, 0.00194 mg/mL, 0.8 mg/mL, 0.3 mg/mL, 0.5 mg/mL

, Tablet, Elixir, Elixir - Oral, Oral, Tablet - Oral, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Injection, solution - Endotracheal; Intramuscular; Intravenous; Subcutaneous, Endotracheal; Intramuscular; Intravenous; Subcutaneous, Parenteral, Injection, Injection - Parenteral, Injection - Intramuscular; Intravenous; Subcutaneous, Solution - Ophthalmic, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Solution, Intramuscular, Injection, solution - Intramuscular, Intravenous, Injection, solution - Intravenous, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Solution - Intramuscular; Intravenous; Subcutaneous, Tablet, extended release, Tablet, extended release - Oral, Liquid - Ophthalmic, Liquid, Liquid - Intravenous, Ointment, Ointment - Ophthalmic, Capsule, Capsule - Oral, Liquid - Oral, Solution - Oral, Injection - Intramuscular, Kit, Kit - Intramuscular, Respiratory (inhalation), Endotracheal; Intramedullary; Intramuscular; Intravenous; Subcutaneous, Injection, solution - Endotracheal; Intramedullary; Intramuscular; Intravenous; Subcutaneous, Intravenous; Parenteral, Injection - Intravenous; Parenteral, Injection - Intravenous, Injection - Endotracheal; Intramedullary; Intramuscular; Intravenous; Subcutaneous

laughing

0.025 mg, , 0.0194 mg/mL, 0.1 mg/mL, 0.0194 mg, 1.0 mg/mL, 4.0 mg/mL, 0.4 mg/mL, 10.0 mg/mL, 0.05 mg/mL, 0.14 mg/mL, 0.0582 mg, 0.4 mg, 0.6 mg, 1.0 %, 0.1 mg, 10.0 mg, 0.8 mg, 0.3 mg, 1.0 mg, 3.0 mg, 0.0097 mg, 0.025 mg/mL, 5.0 mg/mL, 20.0 mg/mL, 2.5 mg/mL, 0.5 mg, 0.01 mg/mg, 0.019 mg/mL, 21.0 mg/mL, 0.03 mg, 0.6 mg/mL, 0.00194 mg/mL, 0.8 mg/mL, 0.3 mg/mL, 0.5 mg/mL

, Tablet, Elixir, Elixir - Oral, Oral, Tablet - Oral, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Injection, solution - Endotracheal; Intramuscular; Intravenous; Subcutaneous, Endotracheal; Intramuscular; Intravenous; Subcutaneous, Parenteral, Injection, Injection - Parenteral, Injection - Intramuscular; Intravenous; Subcutaneous, Solution - Ophthalmic, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Solution, Intramuscular, Injection, solution - Intramuscular, Intravenous, Injection, solution - Intravenous, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Solution - Intramuscular; Intravenous; Subcutaneous, Tablet, extended release, Tablet, extended release - Oral, Liquid - Ophthalmic, Liquid, Liquid - Intravenous, Ointment, Ointment - Ophthalmic, Capsule, Capsule - Oral, Liquid - Oral, Solution - Oral, Injection - Intramuscular, Kit, Kit - Intramuscular, Respiratory (inhalation), Endotracheal; Intramedullary; Intramuscular; Intravenous; Subcutaneous, Injection, solution - Endotracheal; Intramedullary; Intramuscular; Intravenous; Subcutaneous, Intravenous; Parenteral, Injection - Intravenous; Parenteral, Injection - Intravenous, Injection - Endotracheal; Intramedullary; Intramuscular; Intravenous; Subcutaneous

dobutamine stress echocardiography

0.025 mg, , 0.0194 mg/mL, 0.1 mg/mL, 0.0194 mg, 1.0 mg/mL, 4.0 mg/mL, 0.4 mg/mL, 10.0 mg/mL, 0.05 mg/mL, 0.14 mg/mL, 0.0582 mg, 0.4 mg, 0.6 mg, 1.0 %, 0.1 mg, 10.0 mg, 0.8 mg, 0.3 mg, 1.0 mg, 3.0 mg, 0.0097 mg, 0.025 mg/mL, 5.0 mg/mL, 20.0 mg/mL, 2.5 mg/mL, 0.5 mg, 0.01 mg/mg, 0.019 mg/mL, 21.0 mg/mL, 0.03 mg, 0.6 mg/mL, 0.00194 mg/mL, 0.8 mg/mL, 0.3 mg/mL, 0.5 mg/mL

, Tablet, Elixir, Elixir - Oral, Oral, Tablet - Oral, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Injection, solution - Endotracheal; Intramuscular; Intravenous; Subcutaneous, Endotracheal; Intramuscular; Intravenous; Subcutaneous, Parenteral, Injection, Injection - Parenteral, Injection - Intramuscular; Intravenous; Subcutaneous, Solution - Ophthalmic, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Solution, Intramuscular, Injection, solution - Intramuscular, Intravenous, Injection, solution - Intravenous, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Solution - Intramuscular; Intravenous; Subcutaneous, Tablet, extended release, Tablet, extended release - Oral, Liquid - Ophthalmic, Liquid, Liquid - Intravenous, Ointment, Ointment - Ophthalmic, Capsule, Capsule - Oral, Liquid - Oral, Solution - Oral, Injection - Intramuscular, Kit, Kit - Intramuscular, Respiratory (inhalation), Endotracheal; Intramedullary; Intramuscular; Intravenous; Subcutaneous, Injection, solution - Endotracheal; Intramedullary; Intramuscular; Intravenous; Subcutaneous, Intravenous; Parenteral, Injection - Intravenous; Parenteral, Injection - Intravenous, Injection - Endotracheal; Intramedullary; Intramuscular; Intravenous; Subcutaneous

muscarinic side effects

0.025 mg, , 0.0194 mg/mL, 0.1 mg/mL, 0.0194 mg, 1.0 mg/mL, 4.0 mg/mL, 0.4 mg/mL, 10.0 mg/mL, 0.05 mg/mL, 0.14 mg/mL, 0.0582 mg, 0.4 mg, 0.6 mg, 1.0 %, 0.1 mg, 10.0 mg, 0.8 mg, 0.3 mg, 1.0 mg, 3.0 mg, 0.0097 mg, 0.025 mg/mL, 5.0 mg/mL, 20.0 mg/mL, 2.5 mg/mL, 0.5 mg, 0.01 mg/mg, 0.019 mg/mL, 21.0 mg/mL, 0.03 mg, 0.6 mg/mL, 0.00194 mg/mL, 0.8 mg/mL, 0.3 mg/mL, 0.5 mg/mL

, Tablet, Elixir, Elixir - Oral, Oral, Tablet - Oral, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Injection, solution - Endotracheal; Intramuscular; Intravenous; Subcutaneous, Endotracheal; Intramuscular; Intravenous; Subcutaneous, Parenteral, Injection, Injection - Parenteral, Injection - Intramuscular; Intravenous; Subcutaneous, Solution - Ophthalmic, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Solution, Intramuscular, Injection, solution - Intramuscular, Intravenous, Injection, solution - Intravenous, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Solution - Intramuscular; Intravenous; Subcutaneous, Tablet, extended release, Tablet, extended release - Oral, Liquid - Ophthalmic, Liquid, Liquid - Intravenous, Ointment, Ointment - Ophthalmic, Capsule, Capsule - Oral, Liquid - Oral, Solution - Oral, Injection - Intramuscular, Kit, Kit - Intramuscular, Respiratory (inhalation), Endotracheal; Intramedullary; Intramuscular; Intravenous; Subcutaneous, Injection, solution - Endotracheal; Intramedullary; Intramuscular; Intravenous; Subcutaneous, Intravenous; Parenteral, Injection - Intravenous; Parenteral, Injection - Intravenous, Injection - Endotracheal; Intramedullary; Intramuscular; Intravenous; Subcutaneous

prophylaxis of Bradycardia

0.025 mg, , 0.0194 mg/mL, 0.1 mg/mL, 0.0194 mg, 1.0 mg/mL, 4.0 mg/mL, 0.4 mg/mL, 10.0 mg/mL, 0.05 mg/mL, 0.14 mg/mL, 0.0582 mg, 0.4 mg, 0.6 mg, 1.0 %, 0.1 mg, 10.0 mg, 0.8 mg, 0.3 mg, 1.0 mg, 3.0 mg, 0.0097 mg, 0.025 mg/mL, 5.0 mg/mL, 20.0 mg/mL, 2.5 mg/mL, 0.5 mg, 0.01 mg/mg, 0.019 mg/mL, 21.0 mg/mL, 0.03 mg, 0.6 mg/mL, 0.00194 mg/mL, 0.8 mg/mL, 0.3 mg/mL, 0.5 mg/mL

, Tablet, Elixir, Elixir - Oral, Oral, Tablet - Oral, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Injection, solution - Endotracheal; Intramuscular; Intravenous; Subcutaneous, Endotracheal; Intramuscular; Intravenous; Subcutaneous, Parenteral, Injection, Injection - Parenteral, Injection - Intramuscular; Intravenous; Subcutaneous, Solution - Ophthalmic, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Solution, Intramuscular, Injection, solution - Intramuscular, Intravenous, Injection, solution - Intravenous, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Solution - Intramuscular; Intravenous; Subcutaneous, Tablet, extended release, Tablet, extended release - Oral, Liquid - Ophthalmic, Liquid, Liquid - Intravenous, Ointment, Ointment - Ophthalmic, Capsule, Capsule - Oral, Liquid - Oral, Solution - Oral, Injection - Intramuscular, Kit, Kit - Intramuscular, Respiratory (inhalation), Endotracheal; Intramedullary; Intramuscular; Intravenous; Subcutaneous, Injection, solution - Endotracheal; Intramedullary; Intramuscular; Intravenous; Subcutaneous, Intravenous; Parenteral, Injection - Intravenous; Parenteral, Injection - Intravenous, Injection - Endotracheal; Intramedullary; Intramuscular; Intravenous; Subcutaneous

Bronchial Spasm

0.025 mg, , 0.0194 mg/mL, 0.1 mg/mL, 0.0194 mg, 1.0 mg/mL, 4.0 mg/mL, 0.4 mg/mL, 10.0 mg/mL, 0.05 mg/mL, 0.14 mg/mL, 0.0582 mg, 0.4 mg, 0.6 mg, 1.0 %, 0.1 mg, 10.0 mg, 0.8 mg, 0.3 mg, 1.0 mg, 3.0 mg, 0.0097 mg, 0.025 mg/mL, 5.0 mg/mL, 20.0 mg/mL, 2.5 mg/mL, 0.5 mg, 0.01 mg/mg, 0.019 mg/mL, 21.0 mg/mL, 0.03 mg, 0.6 mg/mL, 0.00194 mg/mL, 0.8 mg/mL, 0.3 mg/mL, 0.5 mg/mL

, Tablet, Elixir, Elixir - Oral, Oral, Tablet - Oral, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Injection, solution - Endotracheal; Intramuscular; Intravenous; Subcutaneous, Endotracheal; Intramuscular; Intravenous; Subcutaneous, Parenteral, Injection, Injection - Parenteral, Injection - Intramuscular; Intravenous; Subcutaneous, Solution - Ophthalmic, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Solution, Intramuscular, Injection, solution - Intramuscular, Intravenous, Injection, solution - Intravenous, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Solution - Intramuscular; Intravenous; Subcutaneous, Tablet, extended release, Tablet, extended release - Oral, Liquid - Ophthalmic, Liquid, Liquid - Intravenous, Ointment, Ointment - Ophthalmic, Capsule, Capsule - Oral, Liquid - Oral, Solution - Oral, Injection - Intramuscular, Kit, Kit - Intramuscular, Respiratory (inhalation), Endotracheal; Intramedullary; Intramuscular; Intravenous; Subcutaneous, Injection, solution - Endotracheal; Intramedullary; Intramuscular; Intravenous; Subcutaneous, Intravenous; Parenteral, Injection - Intravenous; Parenteral, Injection - Intravenous, Injection - Endotracheal; Intramedullary; Intramuscular; Intravenous; Subcutaneous

Poisoning

0.025 mg, , 0.0194 mg/mL, 0.1 mg/mL, 0.0194 mg, 1.0 mg/mL, 4.0 mg/mL, 0.4 mg/mL, 10.0 mg/mL, 0.05 mg/mL, 0.14 mg/mL, 0.0582 mg, 0.4 mg, 0.6 mg, 1.0 %, 0.1 mg, 10.0 mg, 0.8 mg, 0.3 mg, 1.0 mg, 3.0 mg, 0.0097 mg, 0.025 mg/mL, 5.0 mg/mL, 20.0 mg/mL, 2.5 mg/mL, 0.5 mg, 0.01 mg/mg, 0.019 mg/mL, 21.0 mg/mL, 0.03 mg, 0.6 mg/mL, 0.00194 mg/mL, 0.8 mg/mL, 0.3 mg/mL, 0.5 mg/mL

, Tablet, Elixir, Elixir - Oral, Oral, Tablet - Oral, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Injection, solution - Endotracheal; Intramuscular; Intravenous; Subcutaneous, Endotracheal; Intramuscular; Intravenous; Subcutaneous, Parenteral, Injection, Injection - Parenteral, Injection - Intramuscular; Intravenous; Subcutaneous, Solution - Ophthalmic, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Solution, Intramuscular, Injection, solution - Intramuscular, Intravenous, Injection, solution - Intravenous, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Solution - Intramuscular; Intravenous; Subcutaneous, Tablet, extended release, Tablet, extended release - Oral, Liquid - Ophthalmic, Liquid, Liquid - Intravenous, Ointment, Ointment - Ophthalmic, Capsule, Capsule - Oral, Liquid - Oral, Solution - Oral, Injection - Intramuscular, Kit, Kit - Intramuscular, Respiratory (inhalation), Endotracheal; Intramedullary; Intramuscular; Intravenous; Subcutaneous, Injection, solution - Endotracheal; Intramedullary; Intramuscular; Intravenous; Subcutaneous, Intravenous; Parenteral, Injection - Intravenous; Parenteral, Injection - Intravenous, Injection - Endotracheal; Intramedullary; Intramuscular; Intravenous; Subcutaneous

Pylorospasm

0.025 mg, , 0.0194 mg/mL, 0.1 mg/mL, 0.0194 mg, 1.0 mg/mL, 4.0 mg/mL, 0.4 mg/mL, 10.0 mg/mL, 0.05 mg/mL, 0.14 mg/mL, 0.0582 mg, 0.4 mg, 0.6 mg, 1.0 %, 0.1 mg, 10.0 mg, 0.8 mg, 0.3 mg, 1.0 mg, 3.0 mg, 0.0097 mg, 0.025 mg/mL, 5.0 mg/mL, 20.0 mg/mL, 2.5 mg/mL, 0.5 mg, 0.01 mg/mg, 0.019 mg/mL, 21.0 mg/mL, 0.03 mg, 0.6 mg/mL, 0.00194 mg/mL, 0.8 mg/mL, 0.3 mg/mL, 0.5 mg/mL

, Tablet, Elixir, Elixir - Oral, Oral, Tablet - Oral, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Injection, solution - Endotracheal; Intramuscular; Intravenous; Subcutaneous, Endotracheal; Intramuscular; Intravenous; Subcutaneous, Parenteral, Injection, Injection - Parenteral, Injection - Intramuscular; Intravenous; Subcutaneous, Solution - Ophthalmic, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Solution, Intramuscular, Injection, solution - Intramuscular, Intravenous, Injection, solution - Intravenous, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Solution - Intramuscular; Intravenous; Subcutaneous, Tablet, extended release, Tablet, extended release - Oral, Liquid - Ophthalmic, Liquid, Liquid - Intravenous, Ointment, Ointment - Ophthalmic, Capsule, Capsule - Oral, Liquid - Oral, Solution - Oral, Injection - Intramuscular, Kit, Kit - Intramuscular, Respiratory (inhalation), Endotracheal; Intramedullary; Intramuscular; Intravenous; Subcutaneous, Injection, solution - Endotracheal; Intramedullary; Intramuscular; Intravenous; Subcutaneous, Intravenous; Parenteral, Injection - Intravenous; Parenteral, Injection - Intravenous, Injection - Endotracheal; Intramedullary; Intramuscular; Intravenous; Subcutaneous

Parkinson Disease

0.025 mg, , 0.0194 mg/mL, 0.1 mg/mL, 0.0194 mg, 1.0 mg/mL, 4.0 mg/mL, 0.4 mg/mL, 10.0 mg/mL, 0.05 mg/mL, 0.14 mg/mL, 0.0582 mg, 0.4 mg, 0.6 mg, 1.0 %, 0.1 mg, 10.0 mg, 0.8 mg, 0.3 mg, 1.0 mg, 3.0 mg, 0.0097 mg, 0.025 mg/mL, 5.0 mg/mL, 20.0 mg/mL, 2.5 mg/mL, 0.5 mg, 0.01 mg/mg, 0.019 mg/mL, 21.0 mg/mL, 0.03 mg, 0.6 mg/mL, 0.00194 mg/mL, 0.8 mg/mL, 0.3 mg/mL, 0.5 mg/mL

, Tablet, Elixir, Elixir - Oral, Oral, Tablet - Oral, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Injection, solution - Endotracheal; Intramuscular; Intravenous; Subcutaneous, Endotracheal; Intramuscular; Intravenous; Subcutaneous, Parenteral, Injection, Injection - Parenteral, Injection - Intramuscular; Intravenous; Subcutaneous, Solution - Ophthalmic, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Solution, Intramuscular, Injection, solution - Intramuscular, Intravenous, Injection, solution - Intravenous, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Solution - Intramuscular; Intravenous; Subcutaneous, Tablet, extended release, Tablet, extended release - Oral, Liquid - Ophthalmic, Liquid, Liquid - Intravenous, Ointment, Ointment - Ophthalmic, Capsule, Capsule - Oral, Liquid - Oral, Solution - Oral, Injection - Intramuscular, Kit, Kit - Intramuscular, Respiratory (inhalation), Endotracheal; Intramedullary; Intramuscular; Intravenous; Subcutaneous, Injection, solution - Endotracheal; Intramedullary; Intramuscular; Intravenous; Subcutaneous, Intravenous; Parenteral, Injection - Intravenous; Parenteral, Injection - Intravenous, Injection - Endotracheal; Intramedullary; Intramuscular; Intravenous; Subcutaneous

Organophosphorus Compounds

0.025 mg, , 0.0194 mg/mL, 0.1 mg/mL, 0.0194 mg, 1.0 mg/mL, 4.0 mg/mL, 0.4 mg/mL, 10.0 mg/mL, 0.05 mg/mL, 0.14 mg/mL, 0.0582 mg, 0.4 mg, 0.6 mg, 1.0 %, 0.1 mg, 10.0 mg, 0.8 mg, 0.3 mg, 1.0 mg, 3.0 mg, 0.0097 mg, 0.025 mg/mL, 5.0 mg/mL, 20.0 mg/mL, 2.5 mg/mL, 0.5 mg, 0.01 mg/mg, 0.019 mg/mL, 21.0 mg/mL, 0.03 mg, 0.6 mg/mL, 0.00194 mg/mL, 0.8 mg/mL, 0.3 mg/mL, 0.5 mg/mL

, Tablet, Elixir, Elixir - Oral, Oral, Tablet - Oral, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Injection, solution - Endotracheal; Intramuscular; Intravenous; Subcutaneous, Endotracheal; Intramuscular; Intravenous; Subcutaneous, Parenteral, Injection, Injection - Parenteral, Injection - Intramuscular; Intravenous; Subcutaneous, Solution - Ophthalmic, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Solution, Intramuscular, Injection, solution - Intramuscular, Intravenous, Injection, solution - Intravenous, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Solution - Intramuscular; Intravenous; Subcutaneous, Tablet, extended release, Tablet, extended release - Oral, Liquid - Ophthalmic, Liquid, Liquid - Intravenous, Ointment, Ointment - Ophthalmic, Capsule, Capsule - Oral, Liquid - Oral, Solution - Oral, Injection - Intramuscular, Kit, Kit - Intramuscular, Respiratory (inhalation), Endotracheal; Intramedullary; Intramuscular; Intravenous; Subcutaneous, Injection, solution - Endotracheal; Intramedullary; Intramuscular; Intravenous; Subcutaneous, Intravenous; Parenteral, Injection - Intravenous; Parenteral, Injection - Intravenous, Injection - Endotracheal; Intramedullary; Intramuscular; Intravenous; Subcutaneous

induction of Cycloplegia

0.025 mg, , 0.0194 mg/mL, 0.1 mg/mL, 0.0194 mg, 1.0 mg/mL, 4.0 mg/mL, 0.4 mg/mL, 10.0 mg/mL, 0.05 mg/mL, 0.14 mg/mL, 0.0582 mg, 0.4 mg, 0.6 mg, 1.0 %, 0.1 mg, 10.0 mg, 0.8 mg, 0.3 mg, 1.0 mg, 3.0 mg, 0.0097 mg, 0.025 mg/mL, 5.0 mg/mL, 20.0 mg/mL, 2.5 mg/mL, 0.5 mg, 0.01 mg/mg, 0.019 mg/mL, 21.0 mg/mL, 0.03 mg, 0.6 mg/mL, 0.00194 mg/mL, 0.8 mg/mL, 0.3 mg/mL, 0.5 mg/mL

, Tablet, Elixir, Elixir - Oral, Oral, Tablet - Oral, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Injection, solution - Endotracheal; Intramuscular; Intravenous; Subcutaneous, Endotracheal; Intramuscular; Intravenous; Subcutaneous, Parenteral, Injection, Injection - Parenteral, Injection - Intramuscular; Intravenous; Subcutaneous, Solution - Ophthalmic, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Solution, Intramuscular, Injection, solution - Intramuscular, Intravenous, Injection, solution - Intravenous, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Solution - Intramuscular; Intravenous; Subcutaneous, Tablet, extended release, Tablet, extended release - Oral, Liquid - Ophthalmic, Liquid, Liquid - Intravenous, Ointment, Ointment - Ophthalmic, Capsule, Capsule - Oral, Liquid - Oral, Solution - Oral, Injection - Intramuscular, Kit, Kit - Intramuscular, Respiratory (inhalation), Endotracheal; Intramedullary; Intramuscular; Intravenous; Subcutaneous, Injection, solution - Endotracheal; Intramedullary; Intramuscular; Intravenous; Subcutaneous, Intravenous; Parenteral, Injection - Intravenous; Parenteral, Injection - Intravenous, Injection - Endotracheal; Intramedullary; Intramuscular; Intravenous; Subcutaneous

Intestines, Small

0.025 mg, , 0.0194 mg/mL, 0.1 mg/mL, 0.0194 mg, 1.0 mg/mL, 4.0 mg/mL, 0.4 mg/mL, 10.0 mg/mL, 0.05 mg/mL, 0.14 mg/mL, 0.0582 mg, 0.4 mg, 0.6 mg, 1.0 %, 0.1 mg, 10.0 mg, 0.8 mg, 0.3 mg, 1.0 mg, 3.0 mg, 0.0097 mg, 0.025 mg/mL, 5.0 mg/mL, 20.0 mg/mL, 2.5 mg/mL, 0.5 mg, 0.01 mg/mg, 0.019 mg/mL, 21.0 mg/mL, 0.03 mg, 0.6 mg/mL, 0.00194 mg/mL, 0.8 mg/mL, 0.3 mg/mL, 0.5 mg/mL

, Tablet, Elixir, Elixir - Oral, Oral, Tablet - Oral, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Injection, solution - Endotracheal; Intramuscular; Intravenous; Subcutaneous, Endotracheal; Intramuscular; Intravenous; Subcutaneous, Parenteral, Injection, Injection - Parenteral, Injection - Intramuscular; Intravenous; Subcutaneous, Solution - Ophthalmic, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Solution, Intramuscular, Injection, solution - Intramuscular, Intravenous, Injection, solution - Intravenous, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Solution - Intramuscular; Intravenous; Subcutaneous, Tablet, extended release, Tablet, extended release - Oral, Liquid - Ophthalmic, Liquid, Liquid - Intravenous, Ointment, Ointment - Ophthalmic, Capsule, Capsule - Oral, Liquid - Oral, Solution - Oral, Injection - Intramuscular, Kit, Kit - Intramuscular, Respiratory (inhalation), Endotracheal; Intramedullary; Intramuscular; Intravenous; Subcutaneous, Injection, solution - Endotracheal; Intramedullary; Intramuscular; Intravenous; Subcutaneous, Intravenous; Parenteral, Injection - Intravenous; Parenteral, Injection - Intravenous, Injection - Endotracheal; Intramedullary; Intramuscular; Intravenous; Subcutaneous

Induced Hyperthermia

0.025 mg, , 0.0194 mg/mL, 0.1 mg/mL, 0.0194 mg, 1.0 mg/mL, 4.0 mg/mL, 0.4 mg/mL, 10.0 mg/mL, 0.05 mg/mL, 0.14 mg/mL, 0.0582 mg, 0.4 mg, 0.6 mg, 1.0 %, 0.1 mg, 10.0 mg, 0.8 mg, 0.3 mg, 1.0 mg, 3.0 mg, 0.0097 mg, 0.025 mg/mL, 5.0 mg/mL, 20.0 mg/mL, 2.5 mg/mL, 0.5 mg, 0.01 mg/mg, 0.019 mg/mL, 21.0 mg/mL, 0.03 mg, 0.6 mg/mL, 0.00194 mg/mL, 0.8 mg/mL, 0.3 mg/mL, 0.5 mg/mL

, Tablet, Elixir, Elixir - Oral, Oral, Tablet - Oral, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Injection, solution - Endotracheal; Intramuscular; Intravenous; Subcutaneous, Endotracheal; Intramuscular; Intravenous; Subcutaneous, Parenteral, Injection, Injection - Parenteral, Injection - Intramuscular; Intravenous; Subcutaneous, Solution - Ophthalmic, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Solution, Intramuscular, Injection, solution - Intramuscular, Intravenous, Injection, solution - Intravenous, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Solution - Intramuscular; Intravenous; Subcutaneous, Tablet, extended release, Tablet, extended release - Oral, Liquid - Ophthalmic, Liquid, Liquid - Intravenous, Ointment, Ointment - Ophthalmic, Capsule, Capsule - Oral, Liquid - Oral, Solution - Oral, Injection - Intramuscular, Kit, Kit - Intramuscular, Respiratory (inhalation), Endotracheal; Intramedullary; Intramuscular; Intravenous; Subcutaneous, Injection, solution - Endotracheal; Intramedullary; Intramuscular; Intravenous; Subcutaneous, Intravenous; Parenteral, Injection - Intravenous; Parenteral, Injection - Intravenous, Injection - Endotracheal; Intramedullary; Intramuscular; Intravenous; Subcutaneous

Rhinorrhea

0.025 mg, , 0.0194 mg/mL, 0.1 mg/mL, 0.0194 mg, 1.0 mg/mL, 4.0 mg/mL, 0.4 mg/mL, 10.0 mg/mL, 0.05 mg/mL, 0.14 mg/mL, 0.0582 mg, 0.4 mg, 0.6 mg, 1.0 %, 0.1 mg, 10.0 mg, 0.8 mg, 0.3 mg, 1.0 mg, 3.0 mg, 0.0097 mg, 0.025 mg/mL, 5.0 mg/mL, 20.0 mg/mL, 2.5 mg/mL, 0.5 mg, 0.01 mg/mg, 0.019 mg/mL, 21.0 mg/mL, 0.03 mg, 0.6 mg/mL, 0.00194 mg/mL, 0.8 mg/mL, 0.3 mg/mL, 0.5 mg/mL

, Tablet, Elixir, Elixir - Oral, Oral, Tablet - Oral, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Injection, solution - Endotracheal; Intramuscular; Intravenous; Subcutaneous, Endotracheal; Intramuscular; Intravenous; Subcutaneous, Parenteral, Injection, Injection - Parenteral, Injection - Intramuscular; Intravenous; Subcutaneous, Solution - Ophthalmic, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Solution, Intramuscular, Injection, solution - Intramuscular, Intravenous, Injection, solution - Intravenous, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Solution - Intramuscular; Intravenous; Subcutaneous, Tablet, extended release, Tablet, extended release - Oral, Liquid - Ophthalmic, Liquid, Liquid - Intravenous, Ointment, Ointment - Ophthalmic, Capsule, Capsule - Oral, Liquid - Oral, Solution - Oral, Injection - Intramuscular, Kit, Kit - Intramuscular, Respiratory (inhalation), Endotracheal; Intramedullary; Intramuscular; Intravenous; Subcutaneous, Injection, solution - Endotracheal; Intramedullary; Intramuscular; Intravenous; Subcutaneous, Intravenous; Parenteral, Injection - Intravenous; Parenteral, Injection - Intravenous, Injection - Endotracheal; Intramedullary; Intramuscular; Intravenous; Subcutaneous

Spasm

0.025 mg, , 0.0194 mg/mL, 0.1 mg/mL, 0.0194 mg, 1.0 mg/mL, 4.0 mg/mL, 0.4 mg/mL, 10.0 mg/mL, 0.05 mg/mL, 0.14 mg/mL, 0.0582 mg, 0.4 mg, 0.6 mg, 1.0 %, 0.1 mg, 10.0 mg, 0.8 mg, 0.3 mg, 1.0 mg, 3.0 mg, 0.0097 mg, 0.025 mg/mL, 5.0 mg/mL, 20.0 mg/mL, 2.5 mg/mL, 0.5 mg, 0.01 mg/mg, 0.019 mg/mL, 21.0 mg/mL, 0.03 mg, 0.6 mg/mL, 0.00194 mg/mL, 0.8 mg/mL, 0.3 mg/mL, 0.5 mg/mL

, Tablet, Elixir, Elixir - Oral, Oral, Tablet - Oral, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Injection, solution - Endotracheal; Intramuscular; Intravenous; Subcutaneous, Endotracheal; Intramuscular; Intravenous; Subcutaneous, Parenteral, Injection, Injection - Parenteral, Injection - Intramuscular; Intravenous; Subcutaneous, Solution - Ophthalmic, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Solution, Intramuscular, Injection, solution - Intramuscular, Intravenous, Injection, solution - Intravenous, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Solution - Intramuscular; Intravenous; Subcutaneous, Tablet, extended release, Tablet, extended release - Oral, Liquid - Ophthalmic, Liquid, Liquid - Intravenous, Ointment, Ointment - Ophthalmic, Capsule, Capsule - Oral, Liquid - Oral, Solution - Oral, Injection - Intramuscular, Kit, Kit - Intramuscular, Respiratory (inhalation), Endotracheal; Intramedullary; Intramuscular; Intravenous; Subcutaneous, Injection, solution - Endotracheal; Intramedullary; Intramuscular; Intravenous; Subcutaneous, Intravenous; Parenteral, Injection - Intravenous; Parenteral, Injection - Intravenous, Injection - Endotracheal; Intramedullary; Intramuscular; Intravenous; Subcutaneous

Urinary Tract Infections

0.025 mg, , 0.0194 mg/mL, 0.1 mg/mL, 0.0194 mg, 1.0 mg/mL, 4.0 mg/mL, 0.4 mg/mL, 10.0 mg/mL, 0.05 mg/mL, 0.14 mg/mL, 0.0582 mg, 0.4 mg, 0.6 mg, 1.0 %, 0.1 mg, 10.0 mg, 0.8 mg, 0.3 mg, 1.0 mg, 3.0 mg, 0.0097 mg, 0.025 mg/mL, 5.0 mg/mL, 20.0 mg/mL, 2.5 mg/mL, 0.5 mg, 0.01 mg/mg, 0.019 mg/mL, 21.0 mg/mL, 0.03 mg, 0.6 mg/mL, 0.00194 mg/mL, 0.8 mg/mL, 0.3 mg/mL, 0.5 mg/mL

, Tablet, Elixir, Elixir - Oral, Oral, Tablet - Oral, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Injection, solution - Endotracheal; Intramuscular; Intravenous; Subcutaneous, Endotracheal; Intramuscular; Intravenous; Subcutaneous, Parenteral, Injection, Injection - Parenteral, Injection - Intramuscular; Intravenous; Subcutaneous, Solution - Ophthalmic, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Solution, Intramuscular, Injection, solution - Intramuscular, Intravenous, Injection, solution - Intravenous, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Solution - Intramuscular; Intravenous; Subcutaneous, Tablet, extended release, Tablet, extended release - Oral, Liquid - Ophthalmic, Liquid, Liquid - Intravenous, Ointment, Ointment - Ophthalmic, Capsule, Capsule - Oral, Liquid - Oral, Solution - Oral, Injection - Intramuscular, Kit, Kit - Intramuscular, Respiratory (inhalation), Endotracheal; Intramedullary; Intramuscular; Intravenous; Subcutaneous, Injection, solution - Endotracheal; Intramedullary; Intramuscular; Intravenous; Subcutaneous, Intravenous; Parenteral, Injection - Intravenous; Parenteral, Injection - Intravenous, Injection - Endotracheal; Intramedullary; Intramuscular; Intravenous; Subcutaneous

Warnings

Motofen has fourteen contraindications and should not be employed for the conditions indicated in the following table.

Motofen Contraindications

Condition

Risk Level

Notes

Liver Diseases

Do Not Combine

Uterine Inertia

Do Not Combine

Intestinal Pseudo-Obstruction

Do Not Combine

unstable cardiovascular status

Do Not Combine

Rapid Heartbeat

Do Not Combine

Chronic Kidney Disease (CKD)

Do Not Combine

Arterial Occlusive Diseases

Do Not Combine

Uterine Inertia

Do Not Combine

Uropathy Obstructive

Do Not Combine

Ulcerative Colitis

Do Not Combine

Ulcerative Colitis

Do Not Combine

Tissue Adhesions

Do Not Combine

Myasthenia Gravis

Do Not Combine

There are 20 known major drug interactions with Motofen.

Common Motofen Drug Interactions

Drug Name

Risk Level

Description

Aclidinium

Major

The risk or severity of adverse effects can be increased when Atropine is combined with Aclidinium.

Anagrelide

Major

The risk or severity of QTc prolongation can be increased when Atropine is combined with Anagrelide.

Arsenic trioxide

Major

The risk or severity of QTc prolongation can be increased when Atropine is combined with Arsenic trioxide.

Artemether

Major

The risk or severity of QTc prolongation can be increased when Atropine is combined with Artemether.

Asenapine

Major

The risk or severity of QTc prolongation can be increased when Atropine is combined with Asenapine.

Motofen Toxicity & Overdose Risk

Overdosing on atropine can cause racing heart, dilated pupils, difficulty swallowing, hot and dry skin, dizziness, trembling, exhaustion and poor coordination. More severe cases may result in confusion and hallucinations, delirium, or even coma and death. Treatment for atropine overdose includes providing artificial respiration and cooling methods to reduce fever, as well as catheterization if necessary. Large doses of sedatives should be avoided, as they may worsen the depression caused by the overdose. The lowest toxic dose of atropine in mice is 75mg/kg.

image of a doctor in a lab doing drug, clinical research

Motofen Novel Uses: Which Conditions Have a Clinical Trial Featuring Motofen?

22 active studies are investigating the use of Motofen to ameliorate Rhinorrhoea, prevent Bradycardia and Slow Heart Rate.

Condition

Clinical Trials

Trial Phases

Slow Heart Rate

2 Actively Recruiting

Not Applicable

hypermobility of the colon

0 Actively Recruiting

Sinus Bradycardia

0 Actively Recruiting

Kidney Calculi

0 Actively Recruiting

Excessive bronchial secretion

0 Actively Recruiting

dobutamine stress echocardiography

0 Actively Recruiting

Intestines, Small

0 Actively Recruiting

Bile fluid

1 Actively Recruiting

Not Applicable

Carbamates

0 Actively Recruiting

Induced Hyperthermia

0 Actively Recruiting

Conjunctivitis

0 Actively Recruiting

Crying

0 Actively Recruiting

Intubation (procedure)

0 Actively Recruiting

Cycloplegia

0 Actively Recruiting

Poisoning by parasympathomimetics (cholinergics)

0 Actively Recruiting

Urinary Bladder, Overactive

0 Actively Recruiting

Lazy Eye

13 Actively Recruiting

Not Applicable, Phase 3, Phase 1, Phase 2

induction of Cycloplegia

0 Actively Recruiting

Urinary Tract Infections

7 Actively Recruiting

Not Applicable, Phase 4

Cholinesterase Inhibitors

0 Actively Recruiting

Motofen Reviews: What are patients saying about Motofen?

5

Patient Review

4/16/2008

Motofen for Diarrhea

I have used this drug for 5 years to manage my IBS. It's been incredibly effective, but unfortunately it has been on backorder from the manufacturer for a while now. I've tried other drugs in the meantime, but nothing works as well as this one did.

5

Patient Review

2/23/2010

Motofen for Diarrhea

Motofen has really improved my quality of life by making it easier to manage my Crohn's. I now feel confident enough to go on outings with my family that I wouldn't have before.

5

Patient Review

2/7/2008

Motofen for Diarrhea

After trying various medications, this one finally worked for me--that is, until I went to refill my prescription and was told by Valeant Pharmaceuticals that it was out of stock and back-ordered until August. It's incredibly frustrating to find something that works only to have it taken away without warning.

5

Patient Review

3/12/2008

Motofen for Diarrhea

I can understand why the other reviewer loved this drug so much. It worked really well for me too, and I'm frustrated that it's no longer available.

5

Patient Review

11/23/2010

Motofen for Diarrhea

Motofen gives me a sense of normalcy that I really appreciate. It's great for car trips or any time when you might not have easy access to a bathroom. I don't know why it's no longer on the market, but please help bring it back!

5

Patient Review

1/3/2019

Motofen for Diarrhea

I'm elated that Motofen is available again! It was the only medication I took for my Crohn's disease and it worked wonders. I've heard similar stories from others who have used the drug, so I know I'm not alone in my experience.

5

Patient Review

7/15/2008

Motofen for Diarrhea

I'm really hoping Motofen will be available again soon. I stocked up on it a while ago, but now I'm down to my last week's worth. Does anyone know what's going on?

5

Patient Review

2/3/2009

Motofen for Diarrhea

I have radiation colitis and this medication has really helped me. It's been a game changer for my quality of life.

5

Patient Review

12/3/2008

Motofen for Diarrhea

I was on this medication for a long time, but had to stop taking it suddenly. Now I'm dealing with the fallout and am looking for other options that can help me.

4.7

Patient Review

7/20/2012

Motofen for Diarrhea

This drug is amazing. I have irritable bowel syndrome and this is the only thing that allows me to not worry about finding a bathroom. So happy it is back on the market!!!
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about motofen

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is Motofen a narcotic?

"Motofen is a combination prescription drug that helps treat severe diarrhea by slowing the contraction of muscles in the intestines so that material moves through at a normal rate. Difenoxin, the primary active ingredient, is also a powerful narcotic that is easily abused."

Answered by AI

What type of drug is Motofen?

"Motofen is a prescription medicine used to treat the symptoms of Diarrhea. It may be used alone or with other medications. Motofen belongs to a class of drugs called Antidiarrheals."

Answered by AI

What is Motofen used for?

"This medication is used to treat diarrhea by decreasing the number and frequency of bowel movements. It works by slowing the movement of the intestines, similar to opioid pain relievers, but it acts mainly to slow the gut."

Answered by AI

What schedule drug is Motofen?

"Motofen is a substance that requires a prescription and falls into the category of drugs that have a potential for abuse. It contains a small amount of atropine sulfate to prevent people from intentionally overdosing on the drug."

Answered by AI

Clinical Trials for Motofen

Image of Children's of Alabama in Birmingham, United States.

Antibiotic Duration for Infections in Children

60 - 17
All Sexes
Birmingham, AL

Infections like pneumonia, skin and soft tissue infection (also called SSTI or cellulitis), and urinary tract infections (UTI) are some of the most common reasons children get admitted to the hospital. All three of these conditions require antibiotics for treatment. Although antibiotics are needed to treat the infection and help children feel better, taking them longer than needed can negatively impact children and their families. Negative impacts include things like the burdens of taking more medications and medication side effects. There are guidelines (instructions) from expert medical organizations that suggest the number of days children need antibiotics, but they give a wide range (between 5 and 14 days). Unfortunately, these guidelines are not based on high-quality studies. National data suggests that doctors often choose on the higher end of this range when writing prescriptions for children in the hospital. Our three caregiver co-investigators, other parents of hospitalized children, doctors, other care providers, and researchers, all believe that additional study is needed to determine the best length of antibiotic treatment that weighs both the benefits and harms of antibiotics. The goal of our study is to understand if 5 total days of antibiotic treatment compared to 10 total days of antibiotic treatment is better for children who have been in the hospital for pneumonia, SSTI, or UTI. We will study this question through a randomized control trial. In other words, half of the children will receive 5-days of antibiotics and the other half will receive 10-days of antibiotics. Children in this study (and their caregivers) will not know how many days of antibiotics they will receive to cure their infection because some children will take a placebo (or a pill without antibiotics in it). Only the pharmacy will know if a child is getting antibiotic or placebo (for days 6-10 of treatment). During the first phase of the trial (feasibility phase), 4 hospitals will enroll children in the study. We plan on enrolling 50 patients during this phase. We are starting with just 4 hospitals, so our study team can create and update our study plans if needed. We will closely review information about how many patients and families agree to participate, and if they have any trouble completing any part of the study. We will also interview families to understand the choice to participate in the study, the choice not to participate in the study, and what it is like to be in the study. During the second study phase, we will enroll 1150 more patients across all 11 hospitals. Families will complete short, daily surveys until the 15th day after they started antibiotics, then a larger survey at day 15, at day 20, and at day 30. These surveys will ask about the child's symptoms and recovery from their illness, how the antibiotics are making them feel, and if they had to go back to their doctor, emergency room, or hospital. The answers to these questions will be combined to measure how well the child did, balancing feeling better and having bad effects from the antibiotics. We will use mathematical tests to determine which antibiotic duration is better for treating these illnesses. We will complete other mathematical tests to see if all children should receive the same length of antibiotics or if certain children should be prescribed shorter courses and others longer courses.

Phase 4
Waitlist Available

Children's of Alabama (+9 Sites)

Sunitha V Kaiser, MD, MSc

Image of Medstar National Rehabilitation Hospital in Washington D.C., United States.

Lactobacillus Crispatus for Urinary Tract Infection

18+
All Sexes
Washington D.C., United States

The goal of this clinical trial is to determine whether Lactobacillus crispatus strains isolated from the lower urinary tracts of adult women can be used as an antibiotic-sparing treatment for urinary symptoms and urinary tract infection (UTI) among adults with neurogenic lower urinary tract dysfunction (NLUTD). The main question\[s\] it aims to answer are: 1. To identify soluble bactericidal compounds produced by urinary isolates of L. crispatus that kill uropathogenic E. coli (UPEC). 2. To determine if intravesical instillation of L. crispatus is safe and well tolerated in adults with NLUTD due to SCI who use intermittent catheterization (IC). If there is a comparison group: Researchers will compare L. Crispatus to standard care saline to see if there is a difference in urinary symptoms and urinary microbiome. Participants will be asked to complete daily symptom surveys, complete 2 bladder instillations, and collect, freeze, and return 14 urine samples.

Phase < 1
Recruiting

Medstar National Rehabilitation Hospital

Suzanne Groah, MD

Image of Baylor College of Medicine in Houston, United States.

Educational Tool for Urinary Tract Infections

18+
All Sexes
Houston, TX

Urine culture is the most common microbiological test in the outpatient setting in the United States. Unfortunately, contamination during collection is prevalent and undermines test accuracy, leading to incorrect diagnosis, unnecessary treatment, wasted laboratory resources, and inflated costs. Unnecessary antibiotic treatment increases the risk of developing antimicrobial resistance, one of the most serious threats to patients and public health. The goal of this clinical trial is to test whether a bilingual (English and Spanish) educational intervention, an animated video and pictorial flyer, can reduce urine culture contamination and associated inappropriate antibiotic use in adult patients visiting safety-net primary care clinics. The main questions it aims to answer are: 1. Does providing patients with a bilingual educational intervention reduce urine culture contamination rates? 2. Does the intervention lead to fewer unnecessary urinary antibiotic prescriptions? 3. Does providing patients with a bilingual educational intervention reduce contaminated urinalyses? Researchers will compare patients randomized to receive the educational intervention (video and flyer) to those receiving usual care to see if the intervention improves urine collection accuracy and reduces inappropriate antibiotic use. Participants will watch a short, animated video with step-by-step instructions for proper midstream clean-catch urine (MSCC) collection, receive a pictorial flyer (with stills from the video) reinforcing the instructions, and provide a urine sample for culture. Hypothesis: patients who receive the educational intervention will have: lower urine culture contamination rates (primary outcome), fewer urinary antibiotic prescriptions (secondary outcome), and fewer contaminated urinalyses (secondary outcome). The objectives are to (1) develop educational tools: Create an animated video and pictorial flyer with step-by-step urine collection instructions for women and men, developed through an iterative, stakeholder-engaged process, (2) assess acceptability: Use mixed methods (quantitative surveys and qualitative interviews) to evaluate and refine the tools for usability and cultural/linguistic appropriateness, and (3) test effectiveness: Conduct a randomized controlled trial to assess the intervention's impact on urine contamination rates, antibiotic prescribing, and patient satisfaction.

Waitlist Available
Has No Placebo

Baylor College of Medicine

Larissa Grigoryan, MD, PhD

Have you considered Motofen clinical trials?

We made a collection of clinical trials featuring Motofen, we think they might fit your search criteria.
Go to Trials
Image of Mayo Clinic in Rochester, United States.

Stent Placement for Gallbladder Disorders

18 - 95
All Sexes
Rochester, MN

This randomized trial will look at whether placing two cystic duct stents is more effective than one cystic duct stent in preventing recurrent gallbladder disease (cholecystitis, gallstone pancreatitis, or biliary colic) among patients who are not immediate surgical candidates for removal of their gallbladder. The study will evaluate the safety profile, including rates of recurrent cholecystitis, biliary colic, and procedure-related complications, and technical success, defined as successful placement of stents into the gallbladder. The main questions it aims to answer are: 1. Does placement of two transpapillary cystic duct stents reduce the risk of recurrent symptomatic gallbladder disease compared to one stent? 2. Is there a difference in procedure-related adverse events (post-ERCP pancreatitis, cholangitis, stent migration) between the two strategies? Researchers will compare outcomes between patients randomized to one stent versus two stents to determine which approach provides better long-term gallbladder drainage and fewer recurrent events. Participants will: Be evaluated for eligibility and provide informed consent prior to undergoing an endoscopic retrograde cholangiopancreatography (ERCP), an endoscopy where a guidewire is placed into the bile duct from the small intestine. They will then undergo ERCP with transpapillary cystic duct stent placement, randomized to one or two stents. All participants will receive standard post-procedure care and follow-up assessments for recurrence, adverse events, and need for reintervention.

Recruiting
Has No Placebo

Mayo Clinic

Eric Vargas

Image of UPMC Magee-Womens Hospital in Pittsburgh, United States.

Catheterization Methods for Postpartum Urinary Problems

18+
All Sexes
Pittsburgh, PA

At least ten percent of patients have postpartum urinary retention or difficulty urinating after birth, which can cause incontinence and other urinary problems long-term. After getting an epidural placed, patients should be numb in their pelvic region. This numbness makes it difficult to feel the need to urinate, so patients need a urinary catheter placed to empty the bladder. Some patients have one catheter placed throughout their labor and others have a catheter placed to empty the bladder then removed every few hours. The investigators are studying whether placing a catheter once or catheterizing multiple times affects the rate of postpartum urinary problems and infection.

Waitlist Available
Has No Placebo

UPMC Magee-Womens Hospital

Anna Binstock, MD

Image of University of California, San Francisco in San Francisco, United States.

Trimethoprim-Sulfamethoxazole for Urinary Tract Infections

13 - 29
All Sexes
San Francisco, CA

The goal of this clinical trial is to learn if a common antibiotic called trimethoprim-sulfamethoxazole (TMP-SMX) can help prevent urinary tract infections (UTIs) in children and young adults who recently had a kidney transplant. Most people take TMP-SMX for about 6 months after getting a kidney transplant. In this study, researchers want to see what happens if people keep taking it for 6 more months. The main questions this study is asking are: * Does TMP-SMX lower the number of UTIs in the first year after transplant? * What side effects or problems do participants have while taking TMP-SMX? Researchers will compare TMP-SMX to a placebo (a look-alike pill that does not contain any medication) to see if TMP-SMX works to prevent UTIs. Participants will: * Take either TMP-SMX or a placebo pill by mouth every day for 6 months * Have three visits to touch base with the study team about any issues * Complete short monthly online surveys about any symptoms or side effects * Share blood and urine test results from their regular transplant clinic visits

Phase 4
Waitlist Available

University of California, San Francisco

Alexandra Bicki, MD

Have you considered Motofen clinical trials?

We made a collection of clinical trials featuring Motofen, we think they might fit your search criteria.
Go to Trials
Image of Atlantic Health in Morristown, United States.

Methenamine for Urinary Tract Infection

18 - 100
Female
Morristown, NJ

Stress urinary incontinence (SUI) affects at least 40% of women in the United States. Synthetic polypropylene mid-urethral slings (MUS) are the gold standard treatment for SUI. Post-operative urinary tract infections (UTI) are one of the most common complications after MUS placement. Some studies have demonstrated that MUS placement can increase the risk of UTI up to 21-34%. Post-operative UTI can lead to significant healthcare and patient burden. This additional burden further contributes to an estimated annual cost of $1.6 billion for UTI management in the United States. With increased antibiotic usage, there is simultaneous increase in bacterial resistance leading to treatment refractory UTI. The investigators prescribe post-operative antibiotics prophylactically for 3 days after MUS placement with or without concurrent pelvic reconstructive surgery based on prior literature recommending post-operative prophylaxis. There is a greater emphasis on limiting antibiotic use given the trend of development of bacterial resistance. There are studies supporting alternatives such as methenamine for recurrent UTI prophylaxis treatment, but there are limited studies evaluating methenamine for UTI prophylaxis after MUS.

Recruiting
Has No Placebo

Atlantic Health

Image of Vanderbilt University Medical Center in Nashville, United States.

Augmented Pacing for Bradycardia

18+
All Sexes
Nashville, TN

The goal of this clinical trial is to learn if backup pacing at an increased rate improves hemodynamics in adults with relative bradycardia, a permanent pacemaker, and cardiogenic shock. The main question it aims to answer is: Does increasing the backup pacing rate to 100 beats per minute lead to improved cardiac index compared to a backup pacing rate of 75 beats per minute Participants who are already hospitalized in the Cardiovascular Intensive Care Unit with a permanent pacemaker and pulmonary artery catheter in place will be enrolled in this study. Participants will be exposed to each pacemaker rate in a randomized order with hemodynamics assessed after 10 minutes at each rate.

Recruiting
Has No Placebo

Vanderbilt University Medical Center

Image of Midwestern University Eye Institute in Downers Grove, United States.

Noninvasive Brain Stimulation for Lazy Eye

18 - 55
All Sexes
Downers Grove, IL

The goal of this randomized controlled trial is to investigate the effectiveness of non-invasive brain stimulation in treating adults with amblyopia. The main questions it aims to answer are: 1. What are the effects of non-invasive brain stimulation on neuronal plasticity in the visual cortex of adults with amblyopia, and does it produce lasting changes? 2. Do cumulative sessions of non-invasive brain stimulation influence neural plasticity and higher-order visual functions in adults with amblyopia? The investigators hypothesize that non-invasive brain stimulation will show a positive cumulative effect after five (5) consecutive days of stimulation on visual perception and function in adults with amblyopia. Participants will be randomized into one of two treatment groups: 1. High-frequency transcranial random noise stimulation (hf-tRNS). 2. Sham stimulation. Researchers will compare baseline measurements of crowded visual acuity, contrast sensitivity, stereoacuity, phosphene thresholds, global motion perception, form pattern recognition and pattern-reversal visual evoked potentials (VEPs) to post-treatment measurements for each group.

Recruiting
Paid Trial

Midwestern University Eye Institute

Image of Boston Children's Hospital Waltham in Boston, United States.

Dichoptic Treatment for Lazy Eye

8 - 12
All Sexes
Boston, MA

Participants eligible for the study will be randomly allocated (1:1:1) to receive either Luminopia dichoptic treatment while wearing optical correction if needed, Vivid Vision dichoptic treatment while wearing optical correction if needed, or continued optical correction alone if needed, with clinical assessments at 9- and 18-weeks post-randomization. At the 18-week primary outcome visit, participants who were randomly assigned to receive optical correction alone if needed with an IOD of 1 logMAR line (5 letters) or more, will be offered randomization to Luminopia or Vivid Vision dichoptic therapy and if they accept, followed forward with visits at 27- and 36-weeks post-randomization. The study will end for all other participants at 18 weeks.

Phase 3
Recruiting

Boston Children's Hospital Waltham (+52 Sites)

Marjean T Kulp, OD

Have you considered Motofen clinical trials?

We made a collection of clinical trials featuring Motofen, we think they might fit your search criteria.
Go to Trials